With an FDA nod, Lilly's oral GLP-1 enters the obesity ring as Foundayo - FirstWord Pharma
FDA Approves Eli Lilly's Obesity Pill, Foundayo - Time Magazine
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
Beyond Diabetes Control: Tirzepatide Boosts Quality of Life
Eli Lilly continue à prendre de l'embonpoint, sur un marché de plus en plus concurrentiel - Les Echos
Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices - Business Wire
Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes - PR Newswire
Opinion | Taking Ozempic (or other GLP-1 drugs) isn’t cheating
Vanessa Williams Has Had A Striking Transformation Thanks To Mounjaro
Tirzepatide Associated with Lower Risk of Heart and Kidney Damage Compared to Dulaglutide in Patients with Type 2 Diabetes and Cardiovascular Disease - Cleveland Clinic Newsroom